anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Control group therapy will consist of increasing upper limb function with the use of both hands. The session include active or active assistive range of motion exercises, unilateral and bimanual activities, balance and strength training or coordination exercises depending on the severity of motor impairment. Similar to group A, daily therapy will be conducted for 40 min/day, 6 days/ week for upto 2 weeks.
Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in  FIG. 1 . The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in  FIG. 9 . Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.
Disclosed is a new system for generating recombinant adenovirus vectors and adenovirus-based expression libraries, by positive selection of recombinants deleted for this endogenous protease gene, which gene is expressibly cloned into another region of the adenoviral genome. In a preferred embodiment, the invention allows positive selection of E1-deleted, protease-deleted recombinant adenovirus vectors comprising an exogenous gene or an expressible piece of exogenous DNA, by providing an expression cassette comprising the protease gene and the exogenous DNA inserted in place of E1 region in a shuttle vector. In vivo recombination of the shuttle vector with a protease-deleted adenoviral genome in suitable non-complementing cells generates viable recombinants only when rescuing the protease cloned in E1 region. Non-recombinant viral genomes are not able to grow due to the deletion of the protease gene, ensuring that only recombinant viral plaques are generated. This positive selection can be used for the generation of a large number of high purity recombinant adenovirus vectors and allows generation of adenovirus-based libraries with diversity exceeding 10<6> clones. <IMAGE> <IMAGE>
Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
Serial casting as one of the applications to treat early-onset scoliosis has been reported efficiently to improve deformity, but no report has focused on the efficacy of braces in the treatment of congenital early-onset scoliosis and comparison with progressive idiopathic early-onset scoliosis. Patients with progressive EOS treated with braces in our institution with a minimum of 4 years follow-up were reviewed. Two groups according to the etiological diagnosis were analyzed and compared: the congenital scoliosis (CS) group and idiopathic scoliosis (IS) group. The success cases and the failure cases were also compared. 27 patients with an average main Cobb angle of 38.19° (20-55) underwent initial bracing at an average age of 55.7 months (24-108), the average follow-up time was 76.19 months (49-117). In IS group the main Cobb angle was corrected to 18.69 ± 12.06° (48.61%) following the first bracing; the final Cobb angle was 23.08 ± 22.15°(38.76%) after brace removal. In CS group the main Cobb angle was corrected to 33.93 ± 10.31°(17.1%) following the first bracing and 37.93 ± 14.74°(3.53%) after brace removal. Both coronal chest width and T1-T12 height increased dramatically from pre-bracing to the last follow-up. Patients diagnosed as IS tended to have a better result in main Cobb angle correction than that of CS (P = 0.049). By the time of last follow-up, 8 patients had undergone surgery, and the operation time was postponed by 68.88 ± 26.43 months. For patients with progressive early-onset scoliosis, bracing is an efficient nonsurgical alternative to casting, and some of them can be cured; if not, eventual surgical intervention can be delayed for a period of time without restrictions on the thoracic cavity.
OBJECTIVE: Bladder outlet obstruction (BOO) results in significant fibrosis in the chronic stage and elevated bladder pressure. Piezo1 is a type of mechanosensitive (MS) channel that directly responds to mechanical stimuli. To identify new targets for intervention in the treatment of BOO-induced fibrosis, this study investigated the impact of high hydrostatic pressure (HHP) on Piezo1 activity and the progression of bladder fibrosis.
METHODS: Immunofluorescence staining was conducted to assess the protein abundance of Piezo1 in fibroblasts from obstructed rat bladders. Bladder fibroblasts were cultured under normal atmospheric conditions (0 cmH2O) or exposed to HHP (50 cmH2O or 100 cmH2O). Agonists or inhibitors of Piezo1, YAP1, and ROCK1 were used to determine the underlying mechanism.
RESULTS: The Piezo1 protein levels in fibroblasts from the obstructed bladder exhibited an elevation compared to the control group. HHP significantly promoted the expression of various pro-fibrotic factors and induced proliferation of fibroblasts. Additionally, the protein expression levels of Piezo1, YAP1, ROCK1 were elevated, and calcium influx was increased as the pressure increased. These effects were attenuated by the Piezo1 inhibitor Dooku1. The Piezo1 activator Yoda1 induced the expression of pro-fibrotic factors and the proliferation of fibroblasts, and elevated the protein levels of YAP1 and ROCK1 under normal atmospheric conditions in vitro. However, these effects could be partially inhibited by YAP1 or ROCK inhibitors.
CONCLUSION: The study suggests that HHP may exacerbate bladder fibrosis through activating Piezo1.
TNKase can cause bleeding, including intracranial hemorrhage and fatal bleeding. Concomitant use of other drugs that impair hemostasis increases the risk of bleeding.

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. 

Avoid intramuscular injections and nonessential handling of the patient for the first few hours following treatment with TNKase. Perform arterial and venous punctures carefully and only as required. To minimize bleeding from noncompressible sites, avoid internal jugular and subclavian venous punctures. If an arterial puncture is necessary during TNKase infusion, use an upper extremity vessel that is accessible to manual compression. Apply pressure for at least 30 minutes.
Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
BACKGROUND: National child obesity rates continue to climb. While neighborhood factors are known to influence childhood weight, more work is needed to further our understanding of these relationships and inform intervention and policy approaches reflective of complex real-world contexts.
METHODS: To evaluate the associations between neighborhood components and childhood overweight/obesity, we analyzed sequential, cross-sectional data from the National Survey of Children's Health collected annually between 2016 and 2021. To characterize the complexity of children's neighborhood environments, several interrelated neighborhood factors were examined: amenities, detractions, support, and safety. We used ordinal logistic regression models to evaluate the associations between these exposures of interest and childhood weight status, adjusting for potential confounders.
RESULTS: Our analytic sample contained 96,858 children representing a weighted population of 28,228,799 children ages 10-17 years. Child weight status was healthy in 66.5%, overweight in 16.8%, and obese in 17.2%. All four neighborhood factors were associated with child weight status. The odds of overweight or obesity generally increased with a decreasing number of amenities and increasing number of detractions, with the highest adjusted odds ratio seen with no amenities and all three possible detractions (1.71; 95% confidence interval [1.31, 2.11]).
CONCLUSIONS: Multiple factors within a child's neighborhood environment were associated with child weight status in this sample representative of the US population aged 10-17 years. This suggests the need for future research into how policies and programs can support multiple components of a healthy neighborhood environment simultaneously to reduce rates of childhood overweight/obesity.
The invention relates to an RGD polypeptide radiopharmaceutical and a preparation method thereof. The RGD polypeptide radiopharmaceutical includes an RGD polypeptide and a radionuclide<99m>Tc, wherein, the RGD polypeptide radiopharmaceutical is an RGD cyclopeptide dimmer, that is, E(L-cRGDxK)2 which is synthesized by dimerizing two RGD polypeptide monomers connected with coupling agent L. The radionuclide<99m>Tc serves to mark the RGD cyclopeptide dimmer through a bifunctional chelating agent HYNIC. A pharmacokinetics modified molecule PKM is further connected between the RGD cyclopeptide dimmer and the bifunctional chelating agent. The RGD polypeptide radiopharmaceutical is <99m>Tc-HYNIC-PKM-E(L-cRGDxK)2. The RGD polypeptide radiopharmaceutical is colorless and transparent liquid injection. The RGD polypeptide radiopharmaceutical provided by the invention has the advantages of further reinforcing the binding affinity and the ingestion of drugs by tumor, and achieving better diagnosiseffect.
PURPOSE:To obtain a therapeutic agent of diseases followed by extraordinary heat accumulation of collagen such as pulmonary fibrosis, hepatic fibrosis, keloid, etc., comprising diethanolamine and a pharmaceutically acceptable salt thereof as an active ingredient. CONSTITUTION:A therapeutic agent for diseases with extraordinary accumulation of collagen, having promoting action on production of procollagen, comprising diethanolamine and a pharmaceutically acceptable salt (e.g. hydrochloride or acetate) thereof as an active ingredient. Pulmonary fibrosis, hepatic fibrosis (including liver cirrhosis or chronic hepatitis), keloid, hypertrophic scar and screloderma may be cited as the diseases followed by extraordinary accumulation of collagen. The agent can be administered to human orally or parenterally by injection or percutaneous medication. A dose of the active ingredient compound is properly 30-1,000mg/time per adult in the case of whole body administration by oral mediation or injection and 1-50mg/time in the case of local administration by percutaneous medication.
A young adult African American female presented with normocytic microangiopathic haemolytic anaemia, elevated lactate dehydrogenase and thrombocytopenia. The patient responded to therapeutic plasma exchanges (TPE) for presumed thrombotic microangiopathy caused by thrombotic thrombocytopenic purpura (TTP). After relapsing, the patient was found to have pancytopenia, megaloblastic bone marrow and low vitamin B12 consistent with pernicious anaemia, which improved with intramuscular B12 and discontinuation of TPE. B12-deficient macrocytosis was not seen at presentation due to concomitant alpha-thalassaemia. Initial clinical/laboratory improvement is attributed to B12 present in TPE plasma. B12 deficiency can mimic TTP. Vigilance is needed regarding atypical presentations of pernicious anaemia.
Cutaneous diseases (such as atopic dermatitis, acne, psoriasis, alopecia and chronic wounds) rank as the fourth most prevalent human disease, affecting nearly one-third of the world's population. Skin diseases contribute to significant non-fatal disability globally, impacting individuals, partners, and society at large. Recent evidence suggests that specific microbes colonising our skin and its appendages are often overrepresented in disease. Therefore, manipulating interactions of the microbiome in a non-invasive and safe way presents an attractive approach for management of skin and hair follicle conditions. Due to its proven anti-microbial and anti-inflammatory effects, blue light (380 - 495nm) has received considerable attention as a possible 'magic bullet' for management of skin dysbiosis. As humans, we have evolved under the influence of sun exposure, which comprise a significant portion of blue light. A growing body of evidence indicates that our resident skin microbiome possesses the ability to detect and respond to blue light through expression of chromophores. This can modulate physiological responses, ranging from cytotoxicity to proliferation. In this review we first present evidence of the diverse blue light-sensitive chromophores expressed by members of the skin microbiome. Subsequently, we discuss how blue light may impact the dialog between the host and its skin microbiome in prevalent skin and hair follicle conditions. Finally, we examine the constraints of this non-invasive treatment strategy and outline prospective avenues for further research. Collectively, these findings present a comprehensive body of evidence regarding the potential utility of blue light as a restorative tool for managing prevalent skin conditions. Furthermore, they underscore the critical unmet need for a whole systems approach to comprehend the ramifications of blue light on both host and microbial behaviour.
The invention discloses a compound preparation for fracture, tracheitis and depression. The oral liquid is manufactured by crushing the following raw materials including acanthopanax bark, radix salviae miltiorrhizae, red peony root, raw rhizoma atractylodis macrocephalae, guangdong earthworm, dipsacus root, drynaria, cinnamon, green tangerine peel, tangerine peel, dried rehmannia root, glycyrrhiza, astragalus root, fleece-flower root, atractylodes rhizome,  phellodendron bark, achyranthes root, stellaria root, wolfberry, large leaf gentian root, peach kernel, parasite scurrula, white muscardine silkworm, curcuma root, polygala root, white peony root, ganoderma and so on, and then sieving, extracting, condensing, sterilizing. The above concentrated solution can also be filtrated, dried, sterilized, blended to make nutrient solution, slurry, pill, or capsule. The invention is pure herbal preparation can effectively treat fracture, necrosis of the femoral head arising at the late stage of fracture, depression, tracheitis, with stable efficacy and no toxicity and side-effect. The period of treatment is short, wherein 6 days is one period of treatment. The effect is fast, and the response time is 6 days. 4 periods of treatment is one cycle, with effective rate of 100%.
PURPOSE:To obtain a monoterpene glycoside useful as an industrial germicide or a bacteriostat because of possession of antimicrobial action and suitable as flavoring agent and cholagogue. CONSTITUTION:A monoterpene glycoside shown by formula I or formula II (R is H or acyl) such as periloside B having the following properties. Properties: colorless needle-like crystal. Melting point: 154-155 deg.C. Molecular formula: C16H24O7. Elemental analysis; C 58.5%, H 7.25%. Solubility: readily soluble in water, methanol, etc., and slightly soluble in ethyl ether. The compound is obtained by extracting leaf part of perilla with a water-soluble organic solvent such as methanol, concentrating the extracted solution, filtering off the precipitate, then extracting the filtrate, from which lipids are removed, with chloroform to give the objective crude fraction and further separating and purifying the objective fraction.
PURPOSE: To prepare a stable solution of a hybrid a interferon that contains as the stabilizer a buffer at a pH of 3.0-5.0 and is useful as a pharmaceutical. CONSTITUTION: A buffer at a pH from 3.0 to 5.0 as glycine/HCl or sodium tosylate is admixed to a hybrid α-interferon as a stabilizer. The buffer is 20-400 mM concentration and the hybrid α-interferon is used at a concentration of 0.1-1.5 mg/ml. In a preferred embodiment, a polyol as mannitol, glucose or sucrose is added in a concentration of 20-500 mM. It can be prepared in the forms of subcutaneous, intramuscular and intravenous injection solutions. When the hybrid α-interferon is medicated in a low-concentration aqueous pH solution, the protein is stabilized, kept at a desirable monomolecular state and dissolved in a solution.
The present invention relates to a quick-acting external-use medicament for treating traumatic injuries and a preparing method thereof. In order to solve the problems of slow acting and poor therapeutic effect existing in the existing medicament, the quick-acting external-use medicament is alcohol leaching liquor comprising traditional Chinese medicine raw materials of 10 wt% to 30 wt% of monkshood root, 2 wt% to 10 wt% of safflower, 2 wt% to 8 wt% of dactylicapnos scanden, 4 wt% to 12 wt% of short-pedicel aconite root, 0.5 wt% to 3.5 wt% of wild ginger and 4 wt% to 12 wt% of rhododendron molle. The dosage of alcohol is from 1.5 to 5 times of the total weight of the raw materials. The alcohol concentration is from 65 DEG to 80 DEG. The lixiviating time of the alcohol is from 10 to 15 days. In the preparing method of the quick-acting external-use medicament, the traditional Chinese medicine raw materials are soaked by the alcohol and then are filtered. Therefore, the quick-acting external-use medicament has the advantages of exact therapeutic effect, quick acting, good detumescence and pain alleviating effect, strong action of removing blood stasis and promoting blood circulation and quick recovery and tissue function.
PURPOSE:To obtain the subject copolymer useful for medicine, capable of efficiently administrating medicines and reducing side effects, as a medicine carrier having orientation, by amidating a copolymer containing maleic acid with an amino group-containing phenylboron acid. CONSTITUTION:Maleic acid and another monomer (e.g. N-vinylpyrrolidone) are dissolved in acetone, mixed with azobisisobutyronitrile as an initiator and polymerized at 50 deg.C for four hours. The prepared polymer is amidated with 3-amino-4-heptafluoropropylphenylboron acid to give the objective copolymer comprising a random copolymer comprising a structural unit of formula I {R<1> is group of formula II (R<1> is F or group of the formula CbF2bX (X is F, H or Cl; (b) is 1-10 integer), etc.; (a) is 1 or 2], etc.; R<2> is r<1> or OH}, N- vinylpyrrolidone unit of formula III and a structural unit such as styrene unit, vinyl acetate unit, isobutylene unit, having the molar ratio of the unit of formula I: the unit of formula III of 1:0.01-100 and 1,000-1,000,000 molecular weight.
The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
Described herein are methods and systems that identify missing interactions in incompletely known datasets represented as complex networks. One example embodiment is a method of identifying missing connections in a complex network. The example method includes accessing an electronic representation of the network. The network includes nodes and links, the nodes represent entities, and the links represent interactions between the entities. The method further includes, for each pair of nodes in the network not directly connected by a link, (i) determining a number of paths connecting the pair of nodes, where each path is a length of at least three connections spanning between the pair of nodes in the network, and (ii) calculating a prediction score for the pair of nodes based on the number of paths connecting the pair of nodes. The method further includes ranking the pairs of nodes based on the prediction scores, resulting in an ordered list of node pairs, and selecting at least a subset of the pairs of nodes based on the ordered list of node pairs. The selected pairs of nodes represent missing connections in the network.
INTRODUCTION: Chronic spontaneous urticaria (CSU) is characterized by persistent or recurrent pruritic lesions that last more than 6 weeks. Patients with CSU may experience sleep disturbances, particularly due to itching. Biological rhythms (chronotypes) are categorized as morningness, intermediate, and eveningness types. This study evaluates the relationship between sleep quality, chronotype, and disease severity in CSU patients.
METHODS: The study included 53 CSU patients and 50 healthy controls. A sociodemographic data form was completed, and the disease severity was determined utilizing the Urticaria Activity Score over 7 days (UAS7). The Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI) scales as well as the Morningness-Eveningness Scale (MEQ) were applied to the participants.
RESULTS: The CSU group had a significantly higher body mass index (BMI) than that of the healthy control group. In terms of sleep and chronotype scales, compared to the control group, the CSU group had higher ISI scores as well as subscale scores on the PSQI subscales, with the exception of habitual sleep efficiency and total PSQI scores. There was no difference between MEQ scores. In the correlation analysis, the UAS7 and PSQI total scores were found to be correlated, whereas in the logistic regression analysis the estimated relative risk of BMI and PSQI total score for CSU was found to be 1.13 and 1.45, respectively.
CONCLUSIONS: When dealing with CSU patients, it is necessary to conduct a sleep quality assessment as part of a holistic evaluation.